Kontigo Care AB (KONT) Fair Value & Analysis
Healthcare · SE · Market cap 49.9M SEK
Fair value as of: Jul 18, 2026
From 2 valuation models · updated today
Share price +10.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 1.33 – kr 2.36 · fair‑value band kr 1.27 – kr 1.87 · the kr 1.50 price screens below the kr 1.56 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Kontigo Care AB (KONT) currently trades at kr 1.50, while our model-based Fair Value estimate is kr 1.56, implying the stock looks roughly 4.3% fairly valued today. We read business quality at 19/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Kontigo Care AB generated revenue of 35.2M SEK at a net margin of -3.7%. Revenue declined 14.5% year over year. It earns a return on equity of -2.5%. The balance sheet holds a net cash position of 14.9M SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 1.27 (bear case) to kr 1.87 (bull case); at kr 1.50, the current price sits within that range. The share trades about 38% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -37% fair-value upside, at 4%, KONT screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Kontigo Care AB (publ) provides health care solutions for addiction treatment in Sweden. It offers Previct Care, a digital support for addiction care and mental illness; and Previct Safety for real-time digital drug testing. The company was incorporated in 2013 and is based in Uppsala, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kontigo Care AB reported revenue of kr 29.1M in FY2025 versus kr 24.5M in FY2021, a compound +4.4%/yr. Reported net income was −kr 2.1M in FY2025.
Is KONT fairly valued? → Check now
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $163.76 | $103.58 | -37% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $57.40 | $23.87 | -58% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $89.72 | $54.47 | -39% |
| Hinge Health, Inc HNGE | $62.98 | $78.43 | +25% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
| 10x Genomics, Inc TXG | $31.04 | $20.68 | -33% |
| Waystar Holding WAY | $18.80 | $14.86 | -21% |
| Ping An Healthcare and Technology Company PANHF | $0.9000 | $0.5700 | -37% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kontigo Care AB (KONT) undervalued?
What is the fair value of KONT?
What is the quality score of KONT?
What is the revenue of Kontigo Care AB (KONT)?
What is the net profit margin of KONT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Kontigo Care AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.